Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SYGNIS Licenses Amplification Buffer to QIAGEN

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
This is the second agreement with QIAGEN within 9 months.

Spanish-German biotech company SYGNIS Pharma AG has signed a licence agreement for the distribution of a new amplification buffer with QIAGEN. This is the first licence agreement for the amplification buffer technology developed by the team led by renowned Professor Margarita Salas at the CSIC laboratory.

The recently granted licence covers a new amplification buffer, a tool used in isothermal amplification, providing superior reaction performance.

“With the new agreement, SYGNIS adds a global reference in the sector in the fields of DNA amplification research and commercial markets. This newly signed agreement shows that SYGNIS is making progress in the commercialization of core technologies and products designed for the DNA sequencing and amplification market. It strengthens the network of relationships we maintain with life science and diagnostics companies in the DNA amplification industry,” SYGNIS’ CEO Pilar de la Huerta commented.

Background

In July 2012, through X-POL, SYGNIS reached an exclusive global licence agreement with QIAGEN for the distribution of the polymerase QualiPhi®.

QualiIPhi® is an upgraded version of phi 29 DNA polymerase. Compared to similar polymerase proteins on the market, the new one exhibits enhanced properties. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, among other applications.

Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are basic in research involving analysis and modification of DNA from any species.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS Reports Financial Results for Fiscal Year 2014
Successful change in product and commercialization strategy with strong focus on proprietary product portfolio.
Saturday, May 09, 2015
SYGNIS Signs Non-exclusive Distribution Agreement with Cambridge Bioscience
Significant expansion of product roll-out into one of the most important life science markets in Europe.
Tuesday, May 05, 2015
SYGNIS Signs Non-Exclusive Distribution Agreement with SOPACHEM
SOPACHEM is a specialized distributor with focus on life sciences, diagnostics, biobanking and analytical applications.
Thursday, March 19, 2015
SYGNIS Reports Financial Results for Fiscal Year 2012
Strategic realignment completed - discontinuation of drug development.
Wednesday, May 01, 2013
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!